Pay in 4 interest-free payments of $5.77 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
No evidence supports it
The answer to maximizing the promise of GLP-1s is to treat patients with a comprehensive approach
Most patients begin to notice weight loss within the first 4-8 weeks of treatment, with continued loss over 12-18 months as the dose is titrated upward
It usually produces less weight loss than tirzepatide, but it has the longest outcomes record in the class: fewer cardiovascular events, slower kidney decline, and years of diabetes-trial safety data
The takeaway for anyone researching timelines: the gap between the 24-week and 48-week readings was substantial, and the curve was still moving at the end
The use of tirzepatide may be the only option for individuals with OSA who refuse or are unable to adhere to CPAP in potentially mitigating the poor health outcomes associated with untreated OSA
